Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the Psychokinetics Q2 2026 earnings conference call. This call is being recorded and all participants are in a listen only mode. After the speaker's remarks, we will open the call to questions. We will allow for one question per participant. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Affairs. Diane, please go ahead. Good afternoon and thanks for joining us on the call today. The slides accompanying today's webcast can be found on the Investors and Media section of our website at cytokinetics.com along with today's press release. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Callos, EVP and Chief Commercial Officer, will discuss the commercial launch of mycorrhizal in the U.S. and Europe. Fady Malik, EVP of R&D, will provide updates related to AfriCampden. Steve Heitner, SVP and Chief Medical Officer, will provide updates related to our ongoing clinical development programs. Sung Lee, EVP and Chief Financial Officer, will provide a financial overview for the quarter and finally Robert will make closing remarks and review key milestones for the year ahead. As you can see on this slide, today's discussion will include forward looking statements which are subject to risks and uncertainties. Please refer to our SEC filings for discussion of these factors. And now I will turn the call over to Robert. Thank you, Diane. And thanks to all for joining us on the call today. The second quarter was another solid...